Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Urology,Oncology
Reference10 articles.
1. Cooperberg M, Meeks W, Fang R, Gaylis F, Catalona W, Makarov D. MP43-03 Active Surveillance for low-risk prostate cancer: time trends and variation in the AUA quality (AQUA) registry. J Urol. 2022;207:e740.
2. Tan WP, Rastinehad AR, Klotz L, Carroll PR, Emberton M, Feller JF, et al. Utilization of focal therapy for patients discontinuing active surveillance of prostate cancer: recommendations of an international Delphi consensus. Urol Oncol. 2021;39:781.e17–e24.
3. Guillaumier S, Peters M, Arya M, Afzal N, Charman S, Dudderidge T, et al. A multicentre study of 5-year outcomes following focal therapy in treating clinically significant nonmetastatic prostate cancer. Eur Urol. 2018;74:422–9.
4. Stabile A, Orczyk C, Hosking-Jervis F, Giganti F, Arya M, Hindley RG, et al. Medium-term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localized prostate cancer. BJU Int. 2019;124:431–40.
5. Nassiri N, Richardson S, Kuppermann D, Brisbane WG, Gonzalez S, Kwan L, et al. Partial gland ablation of prostate cancer: effects of repeat treatment. Urology. 2022;170:161–7.